Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis

Open Access

Peer-reviewed

Research Article

Reader Comments (0)

Prostate cancer
Is the Subject Area "Prostate cancer" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Hepatocellular carcinoma
Is the Subject Area "Hepatocellular carcinoma" applicable to this article?

Thanks for your feedback.
Thyroid carcinoma
Is the Subject Area "Thyroid carcinoma" applicable to this article?

Thanks for your feedback.
Renal cancer
Is the Subject Area "Renal cancer" applicable to this article?

Thanks for your feedback.
Cell death
Is the Subject Area "Cell death" applicable to this article?

Thanks for your feedback.